Patents by Inventor Nigel Ramsden

Nigel Ramsden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230129181
    Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: April 27, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230102488
    Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 30, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230096524
    Abstract: The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 30, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230093755
    Abstract: The invention relates to specified oxazole compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 23, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20230089087
    Abstract: The invention relates to specified carboxylic acid compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of ?1-antitrypsin (A1AT) and may be used in the treatment of a disease or disorder such as ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 13, 2022
    Publication date: March 23, 2023
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON, James Michael TOMLINSON
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20220274932
    Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: March 21, 2022
    Publication date: September 1, 2022
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON
  • Compounds and their use for the treatment of alpha1-antitrypsin deficiency
    Patent number: 11312689
    Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: April 26, 2022
    Assignee: Z FACTOR LIMITED
    Inventors: Nigel Ramsden, David John Fox, James Andrew Huntington
  • COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
    Publication number: 20210332015
    Abstract: The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of ?1-antitrypsin deficiency (A1AD or AATD).
    Type: Application
    Filed: June 11, 2021
    Publication date: October 28, 2021
    Inventors: Nigel RAMSDEN, David John FOX, James Andrew HUNTINGTON
  • Heterocyclyl pyrimidine analogues as TYK2 inhibitors
    Patent number: 9655897
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 23, 2017
    Assignee: Cellzome Limited
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors
    Publication number: 20160184307
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Application
    Filed: March 3, 2016
    Publication date: June 30, 2016
    Inventors: Richard John HARRISON, Nigel RAMSDEN, Jeremy MAJOR, Adeline MOREL, Laura CONVERY, Mihiro SUNOSE, Rosemary LYNCH, Rita ADREGO, Alison JONES
  • Heterocyclyl pyrimidine analogues as TYK2 inhibitors
    Patent number: 9296725
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: March 29, 2016
    Assignee: Cellzome Limited
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
    Patent number: 9242987
    Abstract: The invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: January 26, 2016
    Assignee: Cellzome Limited
    Inventors: Nigel Ramsden, Richard John Harrison, Sally Oxenford, Kathryn Bell, Nelly Piton, Claudio Dagostin, Cyrille Broussard, Andrew Ratcliffe
  • Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors
    Publication number: 20150166513
    Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 18, 2015
    Inventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
  • Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
    Patent number: 9040545
    Abstract: The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: May 26, 2015
    Assignee: Cellzome Limited
    Inventors: Kathryn Bell, Nelly Piton, Claudio Dagostin, Cyrille Boussard, Andrew Ratcliffe, Nigel Ramsden
  • PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150005281
    Abstract: The present invention relates to compounds of formula (I) wherein X, R, Y0, T0A, T0B have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds and their use as medicaments.
    Type: Application
    Filed: December 20, 2012
    Publication date: January 1, 2015
    Inventors: Andrew Hobson, Glynn Addison, Nigel Ramsden, John Harrison
  • Triazole derivatives as kinase inhibitors
    Patent number: 8883820
    Abstract: The invention relates to compounds of formula (I); wherein X and R1 to R5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: November 11, 2014
    Assignee: Cellzome Ltd.
    Inventors: Francis Wilson, Nigel Ramsden, Kathryn Bell, Andrew Cansfield, Svenja Burckhardt, Jess Taylor, Mihiro Sunose, David Middlemiss
  • Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
    Publication number: 20140323504
    Abstract: The present invention relates to compounds of formula (I) wherein X1 to X5, Y, ZA, ZB, R and A have the meaning as cited in the description and the claims. Said compounds are useful as kinase inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as the use as medicaments.
    Type: Application
    Filed: September 20, 2012
    Publication date: October 30, 2014
    Inventors: Claudio Dagostin, Nigel Ramsden
  • Amino triazoles as PI3K inhibitors
    Patent number: 8865699
    Abstract: The invention relates to compounds of formula (I) wherein X, T1 and R1 to R3 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of PI3K, for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: October 21, 2014
    Assignee: Cellzome Ltd.
    Inventors: Nigel Ramsden, Kathryn Bell, Andrew David Cansfield, Jess Taylor, Mihiro Sunose, David Middlemiss, Gitte Neubauer
  • PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140296234
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventors: Rosemary LYNCH, Andrew David CANSFIELD, Helen Sarah NIBLOCK, Daniel HARDY, Jane Elizabeth SCANLON, Rita ADREGO, Nigel RAMSDEN
  • Pyrimidine derivatives as mTOR inhibitors
    Patent number: 8785457
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. The compounds of formula (I) are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 22, 2014
    Assignee: Cellzome Limited
    Inventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Hardy, Jane Elizabeth Scanlon, Rita Adrego, Nigel Ramsden